Literature DB >> 19889136

Treatment of leprosy/Hansen's disease in the early 21st century.

Sophie M Worobec1.   

Abstract

Leprosy, or Hansen's disease (HD), is caused by Mycobacterium leprae, a slowly dividing mycobacterium that has evolved to be an intracellular parasite, causing skin lesions and nerve damage. Less than 5% of people exposed to M. leprae develop clinical disease. Host cell-mediated resistance determines whether an individual will develop paucibacillary or multibacillary disease. Hansen's disease is a worldwide disease with about 150 new cases reported annually in the United States. Effective anti-mycobacterial treatments are available, and many patients experience severe reversal and erythema nodosum leprosum reactions that also require treatment. Leprosy has been the target of a World Health Organization multiple drug therapy campaign to eliminate it as a national public health problem in member countries, but endemic regions persist. In the United States, the National Hansen's Disease Program has primary responsibility for medical care, research, and information.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889136     DOI: 10.1111/j.1529-8019.2009.01274.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  9 in total

1.  Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China.

Authors:  D Wang; L Xu; L Lv; L-Y Su; Y Fan; D-F Zhang; R Bi; D Yu; W Zhang; X-A Li; Y-Y Li; Y-G Yao
Journal:  Genes Immun       Date:  2014-12-18       Impact factor: 2.676

2.  Coinfection of leprosy and tuberculosis.

Authors:  Seema Shetty; Shashikiran Umakanth; Bhawani Manandhar; Pankaj Bahadur Nepali
Journal:  BMJ Case Rep       Date:  2018-03-15

Review 3.  Current approaches and future directions in the treatment of leprosy.

Authors:  Sophie M Worobec
Journal:  Res Rep Trop Med       Date:  2012-08-01

4.  Lepromatous leprosy and perianal tuberculosis: a case report and literature review.

Authors:  Maria Rita Parise-Fortes; Joel Carlos Lastória; Silvio Alencar Marques; Maria Stella Ayres Putinatti; Hamilton Ometto Stolf; Mariângela Ester Alencar Marques; Vidal Haddad
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2014-08-27

5.  Unexpectedly high leprosy seroprevalence detected using a random surveillance strategy in midwestern Brazil: A comparison of ELISA and a rapid diagnostic test.

Authors:  Marco Andrey C Frade; Natália A de Paula; Ciro M Gomes; Sebastian Vernal; Fred Bernardes Filho; Helena B Lugão; Marilda M M de Abreu; Patrícia Botini; Malcolm S Duthie; John S Spencer; Rosa Castália F R Soares; Norma T Foss
Journal:  PLoS Negl Trop Dis       Date:  2017-02-23

6.  The life experience of leprosy families in maintaining interaction patterns in the family to support healing in leprosy patients in Indonesian society. A phenomenological qualitative study.

Authors:  Abd Nasir; Ah Yusuf; Muhammad Yulianto Listiawan; Makhfudli Makhfudli
Journal:  PLoS Negl Trop Dis       Date:  2022-04-08

7.  Bacilloscopy and polymerase chain reaction of slit-skin smears and anti-phenolic glycolipid-I serology for Hansen's disease diagnosis.

Authors:  Filipe Rocha Lima; Natália Aparecida de Paula; Mateus Mendonça Ramos Simões; Gabriel Martins da Costa Manso; Gustavo Sartori Albertino; Giovani Cesar Felisbino; Vanderson Mayron Granemann Antunes; Fernanda André Martins Cruz Perecin; Andrezza Telles Westin; Helena Barbosa Lugão; Marco Andrey Cipriani Frade
Journal:  Front Med (Lausanne)       Date:  2022-08-10

8.  Fixed-duration therapy in leprosy: limitations and opportunities.

Authors:  Munisamy Malathi; Devinder Mohan Thappa
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

9.  Activation and cytokine profile of monocyte derived dendritic cells in leprosy: in vitro stimulation by sonicated Mycobacterium leprae induces decreased level of IL-12p70 in lepromatous leprosy.

Authors:  André Flores Braga; Daniela Ferraz Moretto; Patrícia Gigliotti; Mariela Peruchi; Fátima Regina Vilani-Moreno; Ana Paula Campanelli; Ana Carla Pereira Latini; Anand Iyer; Pranab Kumar Das; Vânia Nieto Brito de Souza
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-07-24       Impact factor: 2.743

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.